THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Several studies have shown that inflammation and matrix degradation have pathogenic effects
on the myocardium by influencing heart contractility, inducing hypertrophy, degrading the
matrix, or enhancing fibrosis, thus contributing to the continuous myocardial remodeling
process.
The sedative and antinausea drug thalidomide has been shown to have both anti-inflammatory
and antioncogenic properties that could be of benefit in case of congestive heart failure
(CHF).
Previous, small investigations have shown an improvement in left ventricular ejection
fraction and a favorable cardiac remodeling during thalidomide therapy.